JUNSHI BIO (688180.SH): Application for clinical trials of injectable JS212 has been accepted.
Junshi Biosciences (688180.SH) has issued an announcement. The company has received approval from the National Medical Products Administration for the issuance of the "Acceptance...".
JUNSHI BIO (688180.SH) announces that the company has received the "Acceptance Notification" issued by the National Medical Products Administration for the clinical trial application of injection JS212 (project code "JS212"). JS212 is a recombinant humanized dual-specific antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), primarily used for the treatment of advanced malignant solid tumors.
Related Articles
Orient: Global Excess Reserves Open, Rare Earth Prices Space Opened
CICC: Maintains GREENTOWN SER (02869) Outperform rating, target price of HKD 6.0.
YSB (09885) net profit increased by 409.7% in 2025, with the acceleration of the incubation of proprietary brands becoming a new profitable engine.
Orient: Global Excess Reserves Open, Rare Earth Prices Space Opened
CICC: Maintains GREENTOWN SER (02869) Outperform rating, target price of HKD 6.0.
YSB (09885) net profit increased by 409.7% in 2025, with the acceleration of the incubation of proprietary brands becoming a new profitable engine.
